Ryan Lynch
Fred Hutch/University of Washington Cancer Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ryan Lynch as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:40 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06745076 · Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaUniversity of Washington · recruiting · Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 · principal investigator
- Ph2NCT05169658 · Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin LymphomaUniversity of Washington · completed · Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma · principal investigator
- Ph1/Ph2NCT04231877 · Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell LymphomaUniversity of Washington · active not recruiting · Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · principal investigator
- Ph1NCT04156828 · Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaUniversity of Washington · terminated · Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma · principal investigator
- Ph2NCT04155840 · Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaUniversity of Washington · terminated · Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT03776864 · Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaUniversity of Washington · terminated · Hodgkin's Lymphoma · principal investigator
- Ph1/Ph2NCT03331341 · Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin LymphomaUniversity of Washington · completed · Classical Hodgkin Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:40 UTC. The ranking covers the 200 most relevant of 48 PubMed records, and a shared surname and initials can bring in a namesake. All 48 on PubMed
- Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.N Engl J Med · 2016426 citationsRCR 13.5
- Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.Sci Transl Med · 2015415 citationsRCR 12.5
- 312 citationsRCR 10.0
- Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.Clin Exp Immunol · 2015230 citationsRCR 7.0
- Prescribed dietary phosphate restriction and survival among hemodialysis patients.Clin J Am Soc Nephrol · 2011104 citationsRCR 3.7
- Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.Br J Haematol · 202084 citationsRCR 3.3
- 81 citationsRCR 7.0
- 56 citationsRCR 1.7
- Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.Lancet Haematol · 202156 citationsRCR 2.8
- The effect of brushing time and dentifrice quantity on fluoride delivery in vivo and enamel surface microhardness in situ.Caries Res · 201052 citationsRCR 3.0